Home
MAZE
MAZE News

Latest MAZE THERAPEUTICS INC (MAZE) News on March 15, 2025

Investing.com

18 days ago

Maze Therapeutics receives positive ratings following recent IPO

Maze Therapeutics doses first subject in Phase II AKD treatment trial

Clinical Trials Arena

a month ago

Maze Therapeutics doses first subject in Phase II AKD treatment trial

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

GlobeNewswire

a month ago

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

MT Newswires

a month ago

Maze Therapeutics Prices Upsized IPO at $16 Per Share

Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs

Bloomberg

a month ago

Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

GlobeNewswire

a month ago

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

Metsera, Maze secure combined $415 million in IPOs

BioPharma Dive

a month ago

Metsera, Maze secure combined $415 million in IPOs

Share on Social Networks: